Verici Dx reports continued growth in its Tutivia kidney transplant testing business during the first half of 2026, with testing revenue increasing 53% as adoption expands across US transplant centres.
Revenue for the six months reaches $1.8 million, compared with $1.9 million in the first half of 2025 and $3.7 million for the full year of 2025. The headline revenue figure is affected by changes elsewhere in the business, but Tutivia continues to show clear growth. Testing revenue increases 53% in the period and continues to grow quarter-on-quarter.
Verici Dx now has 35 US transplant centres using Tutivia. Together, these centres represent 23% of annual kidney transplants in the US, giving the company an expanding base from which to increase testing volumes.
The company says adoption is also becoming more established among newer customers. Three of the recent centres joining the Tutivia network have already moved to high recurring ordering, providing evidence that adoption is progressing beyond initial testing.
Verici Dx’s four business development directors, led by recently appointed Senior Sales Director Keith Gilliard, are supporting the expansion in US transplant centres. The company expects the momentum in Tutivia testing revenue to continue through the second half of 2026 and beyond.
The growth in Tutivia testing is central to Verici Dx’s commercial development. The test is designed for kidney transplant patients and provides information intended to support clinical decision-making around transplant health.
The expanding number of centres using the test provides Verici Dx with a growing commercial base. Increasing recurring orders from existing centres also gives the company an opportunity to increase testing volumes without relying solely on adding new customers.
The US remains a key market for Verici Dx, with the company’s current network of 35 transplant centres covering a significant proportion of annual kidney transplantation activity. Further expansion in the number of centres and increased ordering from existing customers could therefore provide additional scope for Tutivia revenue growth.
The first half of 2026 shows a business where the overall revenue figure remains broadly comparable with the previous year, while the company’s core Tutivia testing activity is expanding. The 53% increase in Tutivia testing revenue and growth in recurring orders point to increasing use of the product across the US transplant centre network.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
